Sotera Health Company — Form 8-K Summary
Reporting date: January 20, 2021. The filing reports entry into a material refinancing amendment and related debt obligations. It does not provide quarterly or annual operating results.
Business Context and Transaction
Sotera Health Company, through Sotera Health Holdings, LLC, amended its First Lien Credit Agreement dated December 13, 2019. The refinancing replaced the existing Initial Term Loans with new Refinancing Loans.
- Aggregate Refinancing Loans: $1.7631 billion, funded at par.
- Existing Initial Term Loans were repaid with refinancing proceeds.
- Accrued interest and other amounts due on the Initial Term Loans were paid with cash on hand.
- Maturity date remained December 13, 2026.
Financial Terms and Liquidity
- ABR Loans bear interest at the applicable ABR plus 1.75%.
- Eurodollar Loans bear interest at the adjusted LIBO rate plus 2.75%.
- A premium equal to 1.00% of principal prepaid applies to Refinancing Loans prepaid in connection with a qualifying repricing transaction entered into on or before the six-month anniversary of the amendment’s effective date.
- The refinancing creates or continues a material financial obligation of the company’s consolidated structure.
- The filing does not provide clear information on cash balances, revolver availability, debt amortization, fees, leverage, interest expense, or liquidity covenants.
Material Changes Versus the Prior Comparable Period
The material change disclosed is the refinancing of the Initial Term Loans with $1.7631 billion of new term loans. The filing states that the maturity date was unchanged; it does not provide the prior loan balance, prior interest spreads, refinancing costs, or quantified changes in annual interest expense.
Guidance, Outlook, Risks, and Unusual Items
- No operating or financial guidance is provided in the filing text.
- The refinancing may affect future interest expense depending on benchmark rates and the proportion of ABR versus Eurodollar borrowings.
- The 1.00% repricing premium may increase costs if the loans are repriced or prepaid during the specified six-month period.
- Cash on hand was used for accrued interest and other amounts owed on the prior term loans, but the filing does not state the amount or resulting liquidity impact.
- The complete Credit Agreement and Refinancing Amendment were to be filed as exhibits to the company’s next Form 10-K; the 8-K’s description is expressly qualified by those documents.
- The company furnished a January 20, 2021 press release as Exhibit 99.1. The Regulation FD disclosure was furnished and not deemed filed for Section 18 liability purposes unless expressly incorporated elsewhere.
Investor Verification Items
- Verify the complete refinancing agreement, including mandatory amortization, covenants, collateral, guarantees, and events of default.
- Confirm the prior Initial Term Loan balance, refinancing fees, and any changes to interest expense or cash flow.
- Assess current benchmark-rate exposure and the split between ABR and Eurodollar borrowings.
- Review subsequent filings for debt balances, liquidity, leverage, covenant compliance, and any repricing or prepayment.
- Confirm the amount of cash used to settle accrued interest and other obligations at refinancing.